comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Association of glucagon-like peptide-1 receptor in type 2 diabetic kidney transplant recipients | Cardiovascular Diabetology Comparing GLP-type therapies for weight
Description
The economics of GLP-1s have undergone several heavy-duty studies and overviews, including one in October 2024 by the U.S
37 , 10601074 e1064 (2025)
Dulaglutide not only achieved glycemic control but also significantly reduced IL-6 and TNF levels and slowed the progression of kidney disease (Tuttle et al
Furthermore, analyses from adverse reporting systems are useful, but are difficult to control for confounding factors that increase the risk of pancreatitis and cancer, such as obesity, alcohol consumption, smoking, and the use of other drugs
How Much Should I Expect to Pay for Mounjaro (Tirzepatide)
